Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Full text links

Actions

Share

Review
.2019 Jul 1;104(7):2473-2489.
doi: 10.1210/jc.2018-00688.

Clinical and Pathological Aspects of Silent Pituitary Adenomas

Affiliations
Review

Clinical and Pathological Aspects of Silent Pituitary Adenomas

Juliana Drummond et al. J Clin Endocrinol Metab..

Abstract

Context: Silent pituitary adenomas are anterior pituitary tumors with hormone synthesis but without signs or symptoms of hormone hypersecretion. They have been increasingly recognized and represent challenging diagnostic issues.

Evidence acquisition: A comprehensive literature search was performed using MEDLINE and EMBASE databases from January 2000 to March 2018 with the following key words: (i) pituitary adenoma/tumor and nonfunctioning; or (ii) pituitary adenoma/tumor and silent. All titles and abstracts of the retrieved articles were reviewed, and recent advances in the field of silent pituitary adenomas were summarized.

Evidence synthesis: The clinical and biochemical picture of pituitary adenomas reflects a continuum between functional and silent adenomas. Although some adenomas are truly silent, others will show some evidence of biochemical hypersecretion or could have subtle clinical signs and, therefore, can be referred to as clinically silent or "whispering" adenomas. Silent tumors seem to be more aggressive than their secreting counterparts, with a greater recurrence rate. Transcription factors for pituitary cell lineages have been introduced into the 2017 World Health Organization guidelines: steroidogenic factor 1 staining for gonadotroph lineage; PIT1 (pituitary-specific positive transcription factor 1) for growth hormone, prolactin, and TSH lineage, and TPIT for the corticotroph lineage. Prospective studies applying these criteria will establish the value of the new classification.

Conclusions: A concise review of the clinical and pathological aspects of silent pituitary adenomas was conducted in view of the new World Health Organization classification of pituitary adenomas. New classifications, novel prognostics markers, and emerging imaging and therapeutic approaches need to be evaluated to better serve this unique group of patients.

Copyright © 2019 Endocrine Society.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
During pituitary development, specific transcription factors are fundamental to the complex process of adenohypophyseal cell differentiation. The three main pathways of cell differentiation and the immunoprofile of each cell lineage are illustrated. GATA2, GATA binding protein-2; PROP1, PROP paired-like homeobox 1 (also called prophet of PIT1); PIT1, POU class 1 homeobox 1 (PUO1F1) or pituitary-specific positive transcription factor 1; TPIT, T-box transcription factor 19 (TBX19).
Figure 2.
Figure 2.
Silent pituitary adenoma is a diagnosis that can be determined by combining the clinical data (clinically nonfunctioning adenoma) and histopathological data (immunostaining for hormones and transcription factors).
Figure 3.
Figure 3.
Continuous spectrum between silent and functioning adenomas.
Figure 4.
Figure 4.
True null cell adenomas are composed of uniform, mildly atypical cells with chromophobic cytoplasm. (A) An example showing sinusoidal, papillary, and pseudopapillary architecture similar to the more common gonadotroph adenomas (hematoxylin and eosin stain, ×10). (B) A case of oncocytoma consisting of large cells with acidophilic, granular cytoplasm (hematoxylin and eosin stain, ×20). (C and D) Prevalence of the different SPAs subtypes according to IHC for anterior pituitary hormones: silent gonadotroph adenomas were the most frequent, followed by null cell (according to the World Health Organization 2004 classification), corticotroph, and GH/prolactin/TSH lineage adenomas. The new classification using IHC for anterior pituitary hormones and transcription factor profiling substantially reduced the number of null cell adenomas. Derived from data from Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015; 26:349-355.
Figure 5.
Figure 5.
Pituitary MRI scans of a silent corticotroph adenoma. (A) T1-weighted MRI sequence and (B) T2-weighted MRI sequence allowing identification of multiple microcysts. [Figure kindly provided by Prof. Bonneville, Lyon, France (130)]. Extension to parasellar structures, invasion of the sellar floor and cystic and hemorrhagic changes can be features of silent corticotroph adenomas. This example of a cystic silent ACTH adenoma type 2 adenoma had invaded both clivus and clinoids and extended superiorly to the third ventricle. (C) Axial contrast-enhanced CT scan). (D) Histologically, the lesion had papillary architecture (hematoxylin and eosin stain, ×20). (Inset) A few neoplastic cells expressed ACTH (immunoperoxidase stain, ×20). (A and B) Derived from data from Bonneville F. Silent corticotroph pituitary adenoma. In: Bonneville JF, Bonneville F, Cattin F, Naggi S, eds. MRI of the Pituitary Gland. Springer; 2016.
Figure 6.
Figure 6.
Silent corticotroph adenoma: noninvasive macroadenoma. (A) Axial contrast-enhanced T1-weighted sequence. (B) Histologic slide showing sheets and acini with uniform, medium-size cells with basophilic cytoplasm (hematoxylin and eosin stain, ×20). (C) Expression of ACTH is diffuse (immunoperoxidase stain, ×10). (D) Neoplastic cells show nuclear expression of the transcription factor TPIT (immunoperoxidase stain, ×10). (E) No expression of PC1/3 was present in the tumor cells (immunoperoxidase stain, ×10).
Figure 7.
Figure 7.
Proposed mechanism for “silencing” of corticotroph adenomas. Reduced PC1/3 activity decreases tumor cell production of ACTH despite increased levels of POMC. Compared with hormone-negative adenomas, POMC gene expression is increased in pituitary tumor samples from patients with Cushing disease (CD) and patients with SCAs; however, transcripts for PC1/3 are present at 30-fold greater levels in those with Cushing disease than in those with SCAs. Derived from data from Jahangiri A, Wagner JR, Pekmezci M, et al. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 2013;73:8-18.
Figure 8.
Figure 8.
A case of a plurihormonal PIT1 adenoma showing the typical diffuse, solid architecture of this tumor type. (A) It was composed of epithelioid cells with eosinophilic cytoplasm, an enlarged nucleus, and prominent nucleolus (hematoxylin and eosin stain, ×40). (B) Some cells expressed PRL (immunoperoxidase stain, ×40). (C) A few tumor cells were positive for TSHβ-subunit (immunoperoxidase stain, ×40). (D) Nuclear expression of the transcription factor PIT1 was ubiquitous (immunoperoxidase stain, ×20).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J; Attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016 . From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24(4):C5–C8. - PubMed
    1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769–4775. - PubMed
    1. Lloyd R, Osamura R, Klöppel G, Rosai J, eds. World Health Organization Classification of Tumours of Endocrine Organs, 4th ed Volume 10 Lyon, France: IARC Publication; 2017.
    1. Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. 2017;28(3):228–243. - PubMed
    1. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Silverchair Information Systems full text link Silverchair Information Systems Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp